Sanofi taps Harvard spinout for oral nanobody delivery work Decibel nets $127M IPO to trial surgical gene therapy delivery ACT bags cash to trial local iontophoresis chemotherapy delivery Tonix inks Inserm pact to expand nasal oxytocin delivery R&D Denali's small sneak peek shows up positives for its Hunter syndrome asset Featured Story | By Nick Paul Taylor Sanofi has teamed up with i2O Therapeutics to create oral nanobody-based medicines. The partners will use i2O’s platform for protecting peptides and proteins to end the need for nanobodies to be given via intravenous or subcutaneous injections. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Decibel Therapeutics has netted $127 million from public investors to develop gene therapies that use a surgical delivery method. The IPO haul will enable Decibel to take a gene therapy treatment for a genetic form of profound hearing loss into clinical trials. read more By Nick Paul Taylor Advanced Chemotherapy Technologies (ACT) has raised money to fund clinical development of its method for delivering gemcitabine directly to tumors. ACT sees the technology as a way to deliver a fatal dose of chemotherapy to tumor cells without causing the side effects associated with systemic administration. read more By Nick Paul Taylor Tonix Pharmaceuticals has licensed oxytocin-based therapeutic technology for the treatment of rare genetic disorder Prader-Willi syndrome. The agreement with French research institute Inserm continues Tonix’s push to expand the use of its nasal oxytocin delivery capabilities. read more By Ben Adams Neurodegenerative biotech and pharma friend Denali has revealed a positive peek at some early Hunter syndrome data. read more Resources Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored by: Catalent Discover the current state of patient-focused dose design through clinical evidence, real-world case studies and patient preference-driven drug design solutions that can help develop better treatments and successful real-world outcomes. Sponsored by: Catalent This eBook features insights from experts in the industry on patient-centric drug development challenges and strategies on advancing drug design and development effectively. Sponsored By: Medidata, a Dassault Systèmes company 8 parameters to optimize your “Path to Virtualization” across site- and patient-centric capabilities in this Sponsor Edition eBook. Sponsored By: LabVantage Solutions Uncover the real impact of “digital transformation” with practical advice to help you plan your own transformative journey to a harmonized digital ecosystem. Sponsored By: Acorn AI, a Medidata Company Acorn AI has developed a flexible and scalable Commercial Data Model that provides pharmaceutical companies with the data-driven insights required to respond to the industry’s ever-changing landscape. Download the whitepaper to learn how Acorn AI’s intuitive data model enables launch success and more. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site. BD&L Summit for Life Sciences March 9–10, 2021 | Virtual Event Learn how therapeutics are successfully launched and commercialized March 24-25, 2021 | 9am-3:30pm EST Latin America Healthcare Compliance Certificate Program April 19, 2021 Learn core elements: pricing, competitive assessments and epidemiology April 28-29, 2021 | 9:00am-3:30pm PST
| 